This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

St Jude Medical Inc. (STJ): Today's Featured Health Services Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

St Jude Medical (
STJ) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day up 0.5%. By the end of trading, St Jude Medical rose $1.28 (2.0%) to $65.31 on average volume. Throughout the day, 3,137,509 shares of St Jude Medical exchanged hands as compared to its average daily volume of 2,550,800 shares. The stock ranged in a price between $64.11-$65.46 after having opened the day at $64.17 as compared to the previous trading day's close of $64.03. Other companies within the Health Services industry that increased today were:
Stereotaxis (
STXS), up 18.5%,
Dehaier Medical Systems (
DHRM), up 14.7%,
Nanosphere (
NSPH), up 10.2% and
Rockwell Medical (
RMTI), up 9.0%.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. St Jude Medical has a market cap of $18.6 billion and is part of the health care sector. Shares are up 3.4% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate St Jude Medical a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates
St Jude Medical as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.